T Poynard

Summary

Country: France

Publications

  1. ncbi request reprint Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience
    Mona Munteanu
    Biopredictive, and Groupe Hospitalier Pitié Salpêtrière, 47 83 boulevard de l Hopital, Paris, France
    J Gastrointestin Liver Dis 17:187-91. 2008
  2. pmc An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS UMR 8149, Paris, France
    PLoS ONE 3:e2573. 2008
  3. pmc Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study
    Helmi M'Kada
    Service de Biochimie Métabolique, Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France
    PLoS ONE 7:e42418. 2012
  4. pmc Assessment of liver fibrosis: noninvasive means
    Thierry Poynard
    , , , CNRS ESA 8149 Paris, France
    Saudi J Gastroenterol 14:163-73. 2008
  5. doi request reprint Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)
    Thierry Poynard
    Assistance Publique Hopitaux de Paris AP HP, University Pierre Marie Curie UPMC, INSERM, UMR_S 938, Liver Center, Paris, France Electronic address
    J Hepatol 60:706-14. 2014
  6. ncbi request reprint Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C
    Thierry Poynard
    Assistance Publique Hopitaux de Paris AP HP, University Pierre Marie Curie UPMC, Liver Center, Paris, France Electronic address
    J Hepatol 59:675-83. 2013
  7. doi request reprint Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard
    Thierry Poynard
    Hepato Gastroenterology, APHP UPMC Liver Center, Paris, France
    J Hepatol 58:928-35. 2013
  8. ncbi request reprint Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study
    Thierry Poynard
    Service d Hepato Gastroenterologie, APHP UPMC Paris Liver Center, Paris, France
    J Hepatol 58:452-9. 2013
  9. doi request reprint Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C
    Thierry Poynard
    UPMC Liver Center, AP HP, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Clin Res Hepatol Gastroenterol 36:455-63. 2012
  10. doi request reprint Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population
    Thierry Poynard
    APHP UPMC Paris Liver Center, Paris, France
    J Hepatol 57:541-8. 2012

Collaborators

Detail Information

Publications151 found, 100 shown here

  1. ncbi request reprint Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience
    Mona Munteanu
    Biopredictive, and Groupe Hospitalier Pitié Salpêtrière, 47 83 boulevard de l Hopital, Paris, France
    J Gastrointestin Liver Dis 17:187-91. 2008
  2. pmc An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS UMR 8149, Paris, France
    PLoS ONE 3:e2573. 2008
    ..We compared the 4-year prognostic value of combining FT-AT and viral load for a better definition of the inactive carrier status...
  3. pmc Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study
    Helmi M'Kada
    Service de Biochimie Métabolique, Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France
    PLoS ONE 7:e42418. 2012
    ..Identification of drug-induced liver disease (DILI) is difficult, even among hospitalized patients. The aim of this pilot study was to assess the impact of a specific strategy for DILI screening...
  4. pmc Assessment of liver fibrosis: noninvasive means
    Thierry Poynard
    , , , CNRS ESA 8149 Paris, France
    Saudi J Gastroenterol 14:163-73. 2008
    ..There is no evidence based data justifying biopsy as a first line estimate of liver fibrosis. Health authorities in some countries have already approved validated biomarkers as the first line procedure for the staging of liver fibrosis...
  5. doi request reprint Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)
    Thierry Poynard
    Assistance Publique Hopitaux de Paris AP HP, University Pierre Marie Curie UPMC, INSERM, UMR_S 938, Liver Center, Paris, France Electronic address
    J Hepatol 60:706-14. 2014
    ..1), esophageal varices (F4.2), and severe complications (F4.3): primary liver cancer, variceal bleeding, or decompensation (ascites, encephalopathy, or jaundice)...
  6. ncbi request reprint Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C
    Thierry Poynard
    Assistance Publique Hopitaux de Paris AP HP, University Pierre Marie Curie UPMC, Liver Center, Paris, France Electronic address
    J Hepatol 59:675-83. 2013
    ..The aim was to estimate the impact of SVR on the dynamic of fibrosis presumed by FibroTest™...
  7. doi request reprint Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard
    Thierry Poynard
    Hepato Gastroenterology, APHP UPMC Liver Center, Paris, France
    J Hepatol 58:928-35. 2013
    ..The aim was to assess the applicability and performances of SWE for the diagnosis of fibrosis as compared with FibroTest (FT) and liver stiffness measurement (LSM) by transient elastography using two probes (TE-M and TE-XL)...
  8. ncbi request reprint Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study
    Thierry Poynard
    Service d Hepato Gastroenterologie, APHP UPMC Paris Liver Center, Paris, France
    J Hepatol 58:452-9. 2013
    ..EPIC(3) included a prospective trial assessing long-term peginterferon alfa-2b (PegIFNα-2b) maintenance therapy in patients with METAVIR fibrosis scores (MFS) of F2 or F3 who previously failed hepatitis C retreatment...
  9. doi request reprint Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C
    Thierry Poynard
    UPMC Liver Center, AP HP, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Clin Res Hepatol Gastroenterol 36:455-63. 2012
    ..The combination between FibroTest(®) and LSM has never been assessed using methods assuming that biopsy is not a perfect gold standard...
  10. doi request reprint Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population
    Thierry Poynard
    APHP UPMC Paris Liver Center, Paris, France
    J Hepatol 57:541-8. 2012
    ..We aimed at validating this concept by comparing LFP using FT vs. biopsy (P1) and then at applying the non-invasive method to a large population (P2)...
  11. doi request reprint Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis
    Thierry Poynard
    Assistance Publique Hopitaux de Paris, Université Pierre et Marie Curie Liver Center, Paris, France
    Clin Gastroenterol Hepatol 10:657-63.e7. 2012
    ..We investigated whether this controversy results from limitations of biopsy analysis for intermediate-stage fibrosis and inappropriate determination of the standard area under the receiver-operator characteristic curve (AUROC)...
  12. pmc Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data
    Thierry Poynard
    APHP UPMC Liver Center, Paris, France
    PLoS ONE 7:e30325. 2012
    ..The aim of this study was to perform an overview of 3 studies which assessed the performance of non-invasive markers of fibrosis (FibroTest), steatosis (SteatoTest) and steato-hepatitis (NashTest, ActiTest) in these patients...
  13. doi request reprint Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard
    Thierry Poynard
    APHP UPMC Liver Center, France
    J Hepatol 56:541-8. 2012
    ..The aim was to assess the relative accuracy of FibroTest, LSM, and biopsy using methods without gold standard in patients with chronic hepatitis C (CHC) and controls...
  14. pmc Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
    Vlad Ratziu
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:6. 2006
    ..The aim of this study was to determine the diagnostic utility of non-invasive markers of fibrosis, validated in chronic viral hepatitis and alcoholic liver disease (FibroTest, FT), in patients with NAFLD...
  15. ncbi request reprint Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Hepatology 38:75-85. 2003
    ..In conclusion, sustained disappearance of the virus is associated with reduction of steatosis in genotype 3 as well as a correction of baseline low serum cholesterol...
  16. ncbi request reprint Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial
    T Poynard
    Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris 6, 47 83 boulevard de l Hopital, CNRS ESA 8067, 75651 Paris Cedex 13, France
    J Viral Hepat 10:197-204. 2003
    ..30 and 0.20, respectively). Hence in nonresponders, a high-dose 48-week regimen of IFN and ribavirin combination was more effective than a regimen with interferon at lower dose and ribavirin for 24 weeks only...
  17. doi request reprint Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy
    Thierry Poynard
    Service d Hepatologie, Université Pierre et Marie Curie Liver Center, hôpital La Pitié Salpêtrière, Paris, France
    Gastroenterology 136:1618-28.e2. 2009
    ..Alternate options are needed for patients who relapse or do not respond to therapy...
  18. doi request reprint Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials
    T Poynard
    Service d Hepatologie, UPMC Liver Center, hôpital La Pitié Salpêtrière, AP HP, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Gastroenterol Clin Biol 33:916-22. 2009
    ..The present report is a review of the evidence-based data published so far...
  19. pmc Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
    Thierry Poynard
    APHP UPMC Liver Center, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, Paris, France
    BMC Gastroenterol 10:40. 2010
    ..One challenge was to use them for estimating the prevalence of fibrosis, identifying independent risk factors and to propose screening strategies in the general population...
  20. ncbi request reprint ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure
    T Poynard
    UPMC Paris Liver Center, AP HP, Paris, France
    Gastroenterol Clin Biol 34:388-96. 2010
    ..ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity validated in patients with chronic hepatitis C (HCV)...
  21. ncbi request reprint Treatment of hepatitis C virus: the first decade
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Semin Liver Dis 24:19-24. 2004
    ..Pegylated interferons used alone or in combination with ribavirin provide improved treatment options for different patient groups with chronic hepatitis C...
  22. ncbi request reprint Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus
    T Poynard
    Pitie Salpetriere, Universite Paris, Paris, France
    J Viral Hepat 16:203-13. 2009
    ..62 to 0.25) (P < 0.0001). FibroTest-ActiTest provides a quantitative estimate of liver fibrosis and necroinflammatory activity in patients with chronic hepatitis B and may be an alternative to reduce the need for liver biopsy...
  23. ncbi request reprint Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation
    T Poynard
    APHP Groupe Hospitalier Pitié Salpétrière, Paris, France
    Aliment Pharmacol Ther 25:733-9. 2007
    ..Biopsy length and fragmentation are known as risk factors of false positive or false negative of biopsy but their quantitative impact on area under the receiver operating characteristic curve variability has not been assessed...
  24. ncbi request reprint Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Clin Chem 50:1344-55. 2004
    ....
  25. ncbi request reprint Treatment of cirrhotic patients in the pegylated interferon era
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Dig Liver Dis 36:S344-8. 2004
    ..Non-invasive biochemical markers of liver fibrosis should facilitate the management...
  26. ncbi request reprint FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?
    Thierry Poynard
    Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Expert Rev Mol Diagn 5:15-21. 2005
    ..The possible causes of false negatives and positives are also better identified. These tests, which are now available in 12 countries, can facilitate the screening and management of the most frequent liver diseases...
  27. ncbi request reprint Biomarkers of liver fibrosis
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    Adv Clin Chem 46:131-60. 2008
    ..Neither biomarkers nor biopsy are sufficient alone to take definitive decision in a given patient and all the clinical and biological data must be taken into account...
  28. ncbi request reprint Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages
    Thierry Poynard
    Assistance Publique Hôpitaux de Paris Groupe Hospitalier Pitié Salpêtrière, Paris, France
    Clin Chem 53:1615-22. 2007
    ..The aim of this study was to assess the relationships between the AUC and the prevalence of each fibrosis stage and to elaborate simple methods of standardization...
  29. ncbi request reprint Viral hepatitis C
    Thierry Poynard
    Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Universite, Paris, France
    Lancet 362:2095-100. 2003
    ..These antiviral treatments reduce liver fibrosis progression and can reverse cirrhosis. Unfortunately, even in developed countries, death due to hepatitis C is increasing because of inadequate detection and treatment...
  30. doi request reprint Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update
    T Poynard
    APHP Service d Hépato Gastroentérologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris 6, CNRS ESA 8149 Paris, France
    Gastroenterol Clin Biol 32:8-21. 2008
    ....
  31. ncbi request reprint [Do the interferons have an antifibrotic action? The hepatologist's point of view]
    T Poynard
    Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, 75651 Paris, France
    Rev Med Interne 23:517s-521s. 2002
    ..The indirect anti-fibrotic effect through the antiviral effect has been considerably improved by the pegylation and the association with ribavirin...
  32. doi request reprint Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies
    Thierry Poynard
    University Pierre and Marie Curie Liver Center, Paris, France
    Antivir Ther 15:617-31. 2010
    ..We aimed to review evidence-based published data of biomarkers that have been validated as non-invasive alternatives to biopsy as end points for HBV and HCV infection trials...
  33. ncbi request reprint Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma
    T Poynard
    Department of Medicine, University Paris VI, Paris, France
    Clin Liver Dis 3:869-81. 1999
    ..Although the number of randomized trials is [figure: see text] small, cumulative data suggest that IFN therapy can reduce the incidence of and the mortality from hepatocellular carcinoma in patients with cirrhosis...
  34. ncbi request reprint Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
    T Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Aliment Pharmacol Ther 15:355-61. 2001
    ..The total number of patients included was 1888, of which 945 received an active drug and 943 a placebo...
  35. ncbi request reprint [Treatment and prevention of hepatitis C]
    T Poynard
    Service d hépato gastro entérologie Groupe hospitalier Pitié La Salpêtrière, Paris
    Rev Prat 50:1100-7. 2000
    ..Treatment of HCV should be systematically discussed in patients coinfected with HIV and HCV...
  36. ncbi request reprint Fibrosis in patients with chronic hepatitis C: detection and significance
    T Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Semin Liver Dis 20:47-55. 2000
    ..There is a major need for noninvasive markers of liver fibrosis. None are clearly useful today for the diagnosis of early stages of fibrosis...
  37. ncbi request reprint Natural history of HCV infection
    T Poynard
    Department of Internal Medicine, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Baillieres Best Pract Res Clin Gastroenterol 14:211-28. 2000
    ..In contrast severe extrahepatic manifestations are rare, with 1% for systemic vasculitis...
  38. ncbi request reprint Appropriateness of liver biopsy
    T Poynard
    Groupe Hospitalier Pitie Salpetriere, Paris, France
    Can J Gastroenterol 14:543-8. 2000
    ..Therefore, further evaluation of the appropriateness of liver biopsy in the practical algorithm of such diseases is needed...
  39. ncbi request reprint Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group
    T Poynard
    Service d Hépato Gastroentérologie Groupe Hospitalier Pitié Salpêtrière, Universite Paris VI, Paris, France
    Hepatology 31:211-8. 2000
    ..For patients who are PCR negative after 24 weeks of treatment, genotyping and baseline viral load, fibrosis stage, gender, and age are useful predictive factors in determining whether to continue an additional 24 weeks of treatment...
  40. ncbi request reprint Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Multi-centre group
    T Poynard
    Service d Hépato Gastroentérologie Groupe Hospitalier Pitié Salpêtrière, Paris, France
    J Hepatol 30:1130-7. 1999
    ..The limited number of donor livers calls for "prioritisation", favouring those patients who will benefit most. The aim was to assess the efficacy of liver transplantation in patients with alcoholic cirrhosis...
  41. ncbi request reprint Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
    T Poynard
    Groupe Hospitalier, Faculté Pitie Salpêtrière, Universite Paris VI, URA CNRS 1484, France
    Lancet 352:1426-32. 1998
    ..The aim of this study was to compare the efficacy and safety of interferon alpha2b in combination with oral ribavirin with interferon alone, for treatment of chronic infection with hepatitis C virus (HCV)...
  42. ncbi request reprint Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c
    T Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Hepatol 34:730-9. 2001
    ..In hepatitis C there is controversy over the linearity of the rate of progression and the significance of gender, mode of infection and viral factors...
  43. pmc Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers
    Thierry Poynard
    APHP Groupe Hospitalier Pitié Salpétrière, Universite Paris VI, CNRS UMR, Paris, France
    PLoS ONE 3:e3857. 2008
    ..The aim was to identify factors associated with LSM accuracy using FT as a non-invasive endpoint and vice versa...
  44. pmc Hirsch index and truth survival in clinical research
    Thierry Poynard
    University Pierre et Marie Curie Assistance Publique Hôpitaux de Paris Liver Center, Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    PLoS ONE 5:e12044. 2010
    ..We hypothesized that publications with a first author having a higher Hirsch' index value (h-I), which quantifies and predicts an individual's scientific research output, should have a longer half-life...
  45. doi request reprint FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program
    Thierry Poynard
    APHP UPMC Liver Center, Paris, France
    J Hepatol 54:227-35. 2011
    ....
  46. doi request reprint Ranking hepatologists: which Hirsch's h-index to prevent the "e-crise de foi-e"?
    Thierry Poynard
    UPMC, Service d Hepato Gastroenterologie, Paris Liver Center, Groupe Hospitalier Pitie Salpetriere, AP HP, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Clin Res Hepatol Gastroenterol 35:375-86. 2011
    ..The aim was to analyze the discordance rates in Hepatology between five h-I assessments from five databases: Scholar, Scopus, Web of Science (WoS), ScholarL restricted to "liver", and a specialty h-I HepaTop...
  47. pmc Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age
    Thierry Poynard
    APHP UPMC Paris Liver Center, Paris, France
    BMC Gastroenterol 11:39. 2011
    ..The aims were to estimate the prevalence of RFPN and of proven failures, and to identify factors associated with their occurrences...
  48. ncbi request reprint Fatigue in patients with chronic hepatitis C
    T Poynard
    Departments of Hepatogastroenterology, hôpital La Pitié Salpêtrière, Paris, France
    J Viral Hepat 9:295-303. 2002
    ..Hence, fatigue is the most frequent extrahepatic manifestation in patients infected with HCV. Fatigue is independently associated with female gender, age over 50 years, cirrhosis, depression and purpura...
  49. ncbi request reprint Truth survival in clinical research: an evidence-based requiem?
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Ann Intern Med 136:888-95. 2002
    ..Factors associated with the survival of truth of clinical conclusions in the medical literature are unknown. The authors hypothesized that conclusions derived from studies using better methodology should have a longer half-life...
  50. doi request reprint FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate
    Thierry Poynard
    APHP UPMC Liver Center, 75013 Paris, France
    Clin Res Hepatol Gastroenterol 35:720-30. 2011
    ..Furthermore the performance of these biomarkers have not been assessed in "intention to diagnose" which takes into account the failures and non-reliable results...
  51. ncbi request reprint Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial
    T Poynard
    Hepatogastroenterology Groupe Hospitalier Pitié Salpêtrière, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    J Viral Hepat 9:128-33. 2002
    ..32 +/- 0.03 at 72 weeks; P=0.05). No significant differences were observed for hyaluronic acid.Hence, this fibrosis index could be used as a surrogate marker of the antifibrotic effect of treatments in patients with chronic hepatitis C...
  52. ncbi request reprint A comparison of fibrosis progression in chronic liver diseases
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, et UPRESA 8067 CNRS, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    J Hepatol 38:257-65. 2003
    ..No study has compared the liver fibrosis progression rates among chronic liver diseases and the risk factors in order to better organize screening strategies...
  53. ncbi request reprint A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers
    C d'Arondel
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    J Viral Hepat 13:182-9. 2006
    ..It achieves a 73% SVR and a significant decrease in fibrosis and activity as estimated by biochemical markers...
  54. ncbi request reprint Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study
    F Imbert-Bismut
    Department of Biochemistry, , Paris, France
    Lancet 357:1069-75. 2001
    ..60 to 1.00 (34% [115] of all patients). INTERPRETATION: A combination of basic serum markers could be used to substantially reduce the number of liver biopsies done in patients with chronic HCV infection...
  55. ncbi request reprint Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
    Y Benhamou
    Service d Hepato Gastroenterologie, Hopital Pitie Salpetriere, Paris, France
    Hepatology 30:1302-6. 1999
    ..Lamivudine (300 mg/d) is effective for the inhibition of HBV replication in HIV-infected patients. However, emergence of lamivudine-resistant HBV may occur in 20% of patients per year...
  56. doi request reprint Causes of death in HIV-infected women: persistent role of AIDS. The 'Mortalité 2000 & 2005' Surveys (ANRS EN19)
    Mojgan Hessamfar-Bonarek
    INSERM, U897, Bordeaux, France
    Int J Epidemiol 39:135-46. 2010
    ..Little is known about the causes of death in human immunodeficiency virus (HIV)-infected women in the era of combination antiretroviral therapy (ART)...
  57. ncbi request reprint Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy
    Y Benhamou
    Service d Hepato Gastroenterologie, Service de Pharmacie, Service de Virologie, Service de Maladies Infectieuses, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Hepatology 34:283-7. 2001
    ....
  58. ncbi request reprint The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C
    R P Myers
    Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Viral Hepat 10:103-10. 2003
    ..36; 95% confidence interval, 0.45 to 4.06; P = 0.58). In conclusion, previous HBV infection does not affect liver histology or the response to IFN-based therapy in patients with chronic hepatitis C...
  59. ncbi request reprint Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia
    V Ratziu
    APHP Hépatologie GHPS, Paris, France
    Aliment Pharmacol Ther 25:207-18. 2007
    ..It is impossible to perform liver biopsy in such a large number of hyperlipidaemic patients to identify patients with advanced liver fibrosis or with steatohepatitis (non-alcoholic steatohepatitis, NASH)...
  60. ncbi request reprint Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
    T Poynard
    Service d Hépato Gastroentérologie Groupe Hospitalier Pitié Salp etrière, Universite Paris VI, Paris, France
    Hepatology 32:1131-7. 2000
    ..This effect was most prominent in patients who achieved a virologic response, those receiving 48 weeks of therapy, and in patients with significant fibrosis at baseline...
  61. pmc Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus
    V Thibault
    Laboratoire de Virologie, Service d Hepato gastro enterologie, Service des Maladies Infectieuses, Groupe Hospitalier Pitie Salpetriere, 75013 Paris, France
    J Clin Microbiol 37:3013-6. 1999
    ..This study demonstrates the emergence of particular genetic profiles in HBV-HIV-coinfected patients experiencing a loss of control of HBV infection despite high doses of lamivudine...
  62. ncbi request reprint Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group
    Y Benhamou
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitié Salpêtrière and UPRES A 8067, Paris, France
    Hepatology 30:1054-8. 1999
    ..HIV seropositivity accelerates HCV-related liver fibrosis progression. In coinfected patients, a low CD4 count, alcohol consumption rate, and age at HCV infection are associated with a higher liver fibrosis progression rate...
  63. ncbi request reprint Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy
    Robert P Myers
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    AIDS 18:75-9. 2004
    ..Pegylated interferon alpha (PEG-IFN-alpha) and ribavirin is the most effective available treatment for chronic hepatitis C virus (HCV) infection. Its role in HIV/HCV-co-infected patients who have failed IFN-based therapy is unclear...
  64. ncbi request reprint Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study
    Y Benhamou
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Lancet 358:718-23. 2001
    ..We assessed the safety and efficacy of a once daily dose of adefovir dipivoxil in an open-label trial for the treatment of lamivudine-resistant HBV infection in HIV-1-infected patients...
  65. ncbi request reprint Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C
    R Morra
    UMR CNRS 8149, Pharmacy Faculty, Paris 5 University, Paris, and Biopredictive, Paris, France
    Aliment Pharmacol Ther 26:847-58. 2007
    ..FibroTest has been validated for the diagnosis of liver fibrosis in patients with chronic hepatitis C...
  66. ncbi request reprint A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, CNRS, Paris, France
    Clin Chem 52:1887-96. 2006
    ..We compared the 5-year prognostic value of the FibroTest with biopsy staging for predicting cirrhosis decompensation and survival in patients with chronic HCV infection...
  67. doi request reprint Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab
    G Geri
    Department of Internal Medicine, Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France
    J Viral Hepat 19:497-500. 2012
    ..No beneficial effects of RTX were evidenced on liver fibrosis progression, but we found interesting correlations with the serum albumin level, FibroTest values and B-cell count...
  68. ncbi request reprint The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C
    R P Myers
    Division of Gastroenterology, hôpital La Pitié Salpêtrière, Paris, France
    J Viral Hepat 10:16-22. 2003
    ..92; P=0.01). Hence the rate of fibrosis progression is an independent predictor of SVR to IFN-based therapy in patients with chronic hepatitis C. This additional factor should be considered in economic models evaluating this condition...
  69. doi request reprint [Adherence to pegylated combination therapy in patients with chronic hepatitis C. Importance of the hepatologist, general practitioner, and nurse]
    C Wartelle-Bladou
    Service d Hepato Gastroenterologie, Centre Hospitalier du Pays d Aix, Avenue des Tamaris, 13616 Aix en Provence cedex 1, France
    Gastroenterol Clin Biol 32:S96-S108. 2008
    ....
  70. doi request reprint Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection
    B Hermeziu
    Pediatric Hepatology and National Reference Centre, Biliary Atresia, Bicetre Hospital, University Paris Sud 11, Assistance Publique Hopitaux de Paris, France
    Gastroenterol Clin Biol 34:16-22. 2010
    ..A prospective evaluation of FT-AT in non-transplanted children with chronic HCV infection would be worthwhile in future...
  71. ncbi request reprint Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients
    Patrick Ingiliz
    Hepatology Department, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 13:895-900. 2008
    ..Adefovir dipivoxil (ADV) has shown its efficacy for treating 3TC-resistant (3TC-R) HBV in HIV-coinfected patients. ADV combined with pegylated interferon (PEG-IFN) has never been evaluated in this population...
  72. ncbi request reprint Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C
    Robert P Myers
    Department of Hepato Gastroenterology, hôpital La Pitié Salpêtrière, Paris, France
    Am J Gastroenterol 97:2419-25. 2002
    ..The aims of this study were: 1) to compare an index of five biochemical markers with historical features; and 2) to determine the utility of combining these features with the five-marker index for the prediction of significant fibrosis...
  73. ncbi request reprint Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients
    Robert P Myers
    Department of Hepatology and Gastroenterology, hôpital La Pitié Salpêtrière, Paris, France
    AIDS 17:721-5. 2003
    ..Our aim was to determine the operating characteristics of a non-invasive index of biochemical markers for the prediction of fibrosis in patients with HIV/HCV co-infection...
  74. ncbi request reprint Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors
    Francoise Imbert-Bismut
    Service of Biochemistry, hôpital La Pitié Salpêtrière, Paris, France
    Clin Chem Lab Med 42:323-33. 2004
    ..075+/-0.004 and 0.068+/-0.004, respectively. The low intra-laboratory and intra-patient variability in Fibrotest and Actitest results confirm Fibrotest and Actitest reliability...
  75. ncbi request reprint Lower expression of CD81 B-cell receptor in lymphoproliferative diseases associated with hepatitis C virus infection
    P Cacoub
    Service de Medecine Interne, hôpital La Pitié Salpêtrière, Bd de l Hopital, Paris Cedex, France
    J Viral Hepat 10:10-5. 2003
    ..89, P = 0.02). In patients with a chronic active HCV infection, the presence of a lymphoproliferative disease, either MC or B-NHL, is associated with lower expression of CD81 and higher expression of CD19 receptor on peripheral B cells...
  76. ncbi request reprint Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update
    T Thevenot
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Viral Hepat 8:48-62. 2001
    ..4%, P < 0.001). In conclusion, we confirm the dose and duration effect of IFN in chronic hepatitis C, and the efficacy of IFN-alpha in the treatment of acute hepatitis and in cirrhotic patients...
  77. ncbi request reprint Risk factors for liver fibrosis progression in patients with chronic hepatitis C
    Mercedes De Torres
    Service d Hépato Gastroentérologie Groupe, Hospitalier Pitié Salpêtrière, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Ann Hepatol 2:5-11. 2003
    ....
  78. ncbi request reprint Relationship between the Fibrotest and portal hypertension in patients with liver disease
    D Thabut
    AP HP Service d Hépato Gastroentérologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Aliment Pharmacol Ther 26:359-68. 2007
    ..The best technique to estimate portal hypertension (PHT) is to measure the hepatic venous pressure gradient (HVPG), which is an invasive method...
  79. ncbi request reprint Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis
    C Goulenok
    Service d Hepato Gastroenterologie, Hopital Pitie Salpetriere, Paris, France
    Aliment Pharmacol Ther 16:361-72. 2002
    ..Randomized controlled trials testing flumazenil in hepatic encephalopathy have shown conflicting results...
  80. ncbi request reprint In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir
    Olivier Lada
    Virology, AP HP Pitié Salpêtrière Hospital, Paris, France
    Antivir Ther 9:353-63. 2004
    ..The excellent activity of TDF on lamivudine-resistant virus independently of the resistance mutation profile offers an interesting treatment alternative to HIV-HBV coinfected patients...
  81. ncbi request reprint Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
    Dominique Thabut
    Services d Hépato gastroentérologie, Group Hospitalier Pitié Salpêtrièe, Paris, France
    Am J Gastroenterol 101:1260-7. 2006
    ....
  82. pmc Immune suppression as the etiology of failure to detect anti-HBc antibodies in patients with chronic hepatitis B virus infection
    V Avettand-Fenoel
    Virology Department, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Clin Microbiol 44:2250-3. 2006
    ....
  83. doi request reprint Natural variability of NS3 protease in patients infected with genotype 4 hepatitis C virus (HCV): implications for antiviral treatment using specifically targeted antiviral therapy for HCV
    S Akhavan
    Department of Virology, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, and Université Pierre et Marie Curie Equipe de Recherche 1 Paris 6 University, Paris, France
    J Infect Dis 200:524-7. 2009
    ..The efficacy of antiprotease in HCV-4-infected patients remains to be proven in large clinical trials...
  84. ncbi request reprint Blood oxidative stress markers are unreliable markers of hepatic steatosis
    D Bonnefont-Rousselot
    Laboratoire des Lipides, Groupe Hosptalier Pitie Salpetriere AP HP, Paris, France
    Aliment Pharmacol Ther 23:91-8. 2006
    ..Non-alcoholic fatty liver disease (NAFLD) and viral hepatitis are associated with hepatic oxidative stress, which is partially dependent on the amount of hepatic fat...
  85. ncbi request reprint Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study
    C Bonny
    Service d Hepato Gastroenterologie, Hotel Dieu, Clermont Ferrand, France
    Aliment Pharmacol Ther 24:593-600. 2006
    ..To assess the rate of sustained virological response in naïve hepatitis C virus-type 5 patients treated by standard interferon or pegylated-interferon [corrected] (peg-interferon) and ribavirin combination for 48 weeks...
  86. ncbi request reprint The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV
    Heidi Hannon
    Nephrology Department, Hôpital Pitié Salpétrière and CNRS UPRESA 8087, Paris, France
    Nephrol Dial Transplant 19:386-90. 2004
    ..Recently, lower doses of ADV were shown to be effective for the treatment of HIV-1 patients with chronic lamivudine (LAM)-resistant hepatitis B...
  87. ncbi request reprint FibroMAX: towards a new universal biomarker of liver disease?
    Rachel Morra
    Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Expert Rev Mol Diagn 7:481-90. 2007
    ..The possible causes of false-negative and false-positive results are also better identified. These tests, which are now available in 50 countries, can facilitate the screening and management of the most frequent liver diseases...
  88. ncbi request reprint Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial
    Laetitia Fartoux
    AP HP, Hopital Saint Antoine, Paris, France
    Clin Gastroenterol Hepatol 5:502-7. 2007
    ..We designed a randomized controlled trial comparing the efficacy of prolonged IFN alfa-2a treatment vs nontreatment on complication-free survival in patients with compensated HCV cirrhosis...
  89. ncbi request reprint Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B
    Robert P Myers
    Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Hepatol 39:222-30. 2003
    ..Liver biopsy is the gold standard for assessing hepatitis B virus (HBV)-related histology. The aim was to determine the diagnostic utility of noninvasive serum markers in patients with chronic hepatitis B...
  90. ncbi request reprint Continuous infusion of high-dose omeprazole is more effective than standard-dose omeprazole in patients with high-risk peptic ulcer bleeding: a retrospective study
    M Simon-Rudler
    Service d hépatologie et de gastroentérologie, hôpital Pitié Salpêtrière AP HP, Paris, France
    Aliment Pharmacol Ther 25:949-54. 2007
    ..High-dose omeprazole reduces the rate of recurrent bleeding after endoscopic treatment of peptic ulcer bleeding. However, the effectiveness of high-dose vs. standard-dose omeprazole in peptic ulcer bleeding has never been shown...
  91. ncbi request reprint Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability
    V Ratziu
    Université Pierre et Marie Curie and Assistance Publique, Hôpitaux de Pairs, Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Aliment Pharmacol Ther 26:821-30. 2007
    ..In non-alcoholic fatty liver disease, histological lesions display a significant sampling variability that is ignored when interpreting histological progression during natural history or therapeutic interventions...
  92. ncbi request reprint A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients
    E Bruckert
    Department of Endocrinology, INSERM U 551 and IFR Caeur Muscle Vaisseau, Paris, France
    Metabolism 51:1071-6. 2002
    ..Because these abnormalities may not only be reversible but also associated with a poor prognosis, further studies are needed to identify those dyslipidemic patients who are at risk for the development of severe hepatic tissue damage...
  93. ncbi request reprint Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B
    Dominique Thabut
    Hepato Gastroenterology Unit, Hopital Pitie Salpetriere, Paris, France
    Eur J Gastroenterol Hepatol 16:1367-73. 2004
    ..The clinical features, course and viral mutations associated with the emergence of viral resistance in this population have not been well studied...
  94. ncbi request reprint Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Gastroenterology 122:1303-13. 2002
    ..Liver fibrosis is an important prognostic factor in patients with hepatitis C. The effect of pegylated (PEG) interferon alone or its combination with ribavirin on fibrosis has not been established...
  95. pmc Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
    Thierry Poynard
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:34. 2006
    ..The aim was to develop and validate a new biomarker of non alcoholic steato hepatitis (NASH) the NashTest (NT) in patients with NAFLD...
  96. doi request reprint Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy
    Patrick Ingiliz
    Hepatology Department, AP HP, GH Pitié Salpétrière, Paris, France
    Hepatology 49:436-42. 2009
    ..Conclusions: HIV-infected patients on combined antiretroviral therapy with chronic transaminase elevation of unknown origin have a high rate of liver lesions, mostly consistent with NASH related to insulin resistance...
  97. doi request reprint Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes
    Sophie Jacqueminet
    Service de Diabetologie, APHP GHPS, Paris, France
    Clin Gastroenterol Hepatol 6:828-31. 2008
    ..We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) in patients with diabetes...
  98. ncbi request reprint Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection
    Thierry Poynard
    Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Am J Gastroenterol 100:1970-80. 2005
    ..The aim was to use these markers in a prospective study of patients treated with lamivudine in order to assess the impact of treatment, as well as the factors associated with fibrosis progression...